RENCA/carbonic anhydrase-IX: A murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma

Urology

Volumn 68, Issue 5, 2006, Pages 1132-1138

  Shvarts, Oleg ^a   Janzen, Nicolette ^a   Lam, John S ^a   Leppert, John T ^a   Caliliw, Randy ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a   Zeng, Gang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION; INOCULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C;

EID: 33750973350     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1073     Document Type: Article

References (23)

1. Skinner D.G., Colvin R.B., Vermillion C.D., et al. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 28 (1971) 1165-1177
2. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663-1671
3. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 3 suppl 1 (1997) S92-S97
4. Ko Y.J., and Atkins M.B. Chemotherapies and immunotherapies for metastatic kidney cancer. Curr Urol Rep 6 (2005) 35-42
5. Hanada K., Perry-Lalley D.M., Ohnmacht G.A., et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 61 (2001) 5511-5516
6. Grabmaier K., Vissers J.L., De Weijert M.C., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85 (2000) 865-870
7. Bui M.H.T., Seligson D., Han K.-R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
8. Ivanov S., Liao S.-Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 (2001) 905-919
9. Vissers J.L., De Vries I.J., Schreurs M.W., et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59 (1999) 5554-5559
10. Vissers J.L., De Vries I.J., Engelen L.P., et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 100 (2002) 441-444
11. Wiltrout R.H., Gregorio T.A., Fenton R.G., et al. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol 22 (1995) 9-16
12. Lu X., Kallinteris N.L., Li J., et al. Tumor immunotherapy by converting tumor cells to MHC class II-positive, II protein-negative phenotype. Cancer Immunol Immunother 52 (2003) 592-598
13. Hernandez J.M., Bui M.H., Han K.R., et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9 (2003) 1906-1916
14. Wang R.F., Wang X., Johnston S.L., et al. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res 58 (1998) 3519-3525
15. Wykoff C.C., Beasley N., Watson P.H., et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158 (2001) 1011-1019
16. Ivanov S.V., Kuzmin I., Wei M.H., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95 (1998) 12596-12601
17. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
18. Kim H.L., Seligson D., Liu X., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 (2004) 5464-5471
19. Gut M.O., Parkkila S., Vernerova Z., et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 123 (2002) 1889-1903
20. Mukouyama H., Janzen N.K., Hernandez J.M., et al. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10 (2004) 1421-1429
21. Zisman A., Pantuck A.J., Bui M., et al. LABAZ1: a metastatic tumor model for renal cell carcinoma expressing the CA-IX tumor antigen. Cancer Res 63 (2003) 4952-4959
22. Knoll K., Wrasidlo W., Scherberich J.E., et al. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1. Cancer Res 60 (2000) 6089-6094
23. Liu A., Hu P., Khawli L.A., et al. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 11 (2005) 8492-8502